Mechanistic view of risk factors for venous thromboembolism

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 3, 2012, Pages 563-568

  Reitsma, Pieter H ^a   Versteeg, Henri H ^a   Middeldorp, Saskia ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

endothelium; platelets; pulmonary embolism; risk factors; Venous thrombosis

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; LUPUS ANTICOAGULANT; PADGEM PROTEIN;

ADAPTIVE IMMUNITY; ARTICLE; BED REST; BLOOD CLOTTING; BLOOD FLOW; CARDIOVASCULAR RISK; CHEMOTHERAPY; ENDOTHELIUM; ERYTHROCYTE; ERYTHROCYTOSIS; HEREDITY; HORMONE SUBSTITUTION; HUMAN; INFECTION; INFLAMMATORY DISEASE; INJURY; INNATE IMMUNITY; MEMBRANE MICROPARTICLE; OBESITY; ORAL CONTRACEPTION; ORTHOPEDIC SURGERY; OXYGEN TENSION; PLASTER CAST; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; SMOKING; THROMBOCYTE; UPREGULATION; VENOUS THROMBOEMBOLISM;

ADAPTIVE IMMUNITY; ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; CELL-DERIVED MICROPARTICLES; ENDOTHELIAL CELLS; ERYTHROCYTES; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; OXYGEN; REGIONAL BLOOD FLOW; RISK ASSESSMENT; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84857541896     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.242818     Document Type: Article

References (81)

1. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5:692-699. (Pubitemid 46563566)
2. Virchow R. Thrombose und embolie. Gefässentzündung und septische infektion. Gesammelte Abhandlungen zur wissenschaftlichen Medicin. Frankfurt am Main: Von Meidinger & Sohn. 1856:219-732.
3. Bovill EG, van der Vliet A. Venous valvular stasis-associated hypoxia and thrombosis: What is the link? Annu Rev Physiol. 2011;73:527-545.
4. Acker T, Fandrey J, Acker H. The good, the bad and the ugly in oxygen-sensing: Ros, cytochromes and prolyl-hydroxylases. Cardiovasc Res. 2006;71:195-207.
5. Lopez JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology Am Soc Hematol Educ Program. 2004:439-456.
6. Manly DA, Boles J, Mackman N. Role of tissue factor in venous thrombosis. Annu Rev Physiol. 2011;73:515-525.
7. Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, Song Y, Tzima E, Kennerknecht E, Niepmann M, von Bruehl ML, Sedding D, Massberg S, Gunther A, Engelmann B, Preissner KT. Extracellular rna constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA. 2007;104:6388-6393. (Pubitemid 47186104)
8. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD Jr, Wrobleski SK, Wakefield TW, Hartwig JH, Wagner DD. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA. 2010;107:15880-15885.
9. Muller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM, Schmidbauer S, Gahl WA, Morrissey JH, Renne T. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell. 2009;139:1143-1156.
10. Sasahara AA, Sharma GV, Barsamian EM, Schoolman M, Cella G. Pulmonary thromboembolism: diagnosis and treatment. JAMA. 1983;249: 2945-2950.
11. Bergqvist D, Lowe G. Venous thromboembolism in patients undergoing laparoscopic and arthroscopic surgery and in leg casts. Arch Intern Med. 2002;162:2173-2176. (Pubitemid 35231584)
12. Demers C, Marcoux S, Ginsberg JS, Laroche F, Cloutier R, Poulin J. Incidence of venographically proved deep vein thrombosis after knee arthroscopy. Arch Intern Med. 1998;158:47-50. (Pubitemid 28070445)
13. Schreijer AJ, Hoylaerts MF, Meijers JC, Lijnen HR, Middeldorp S, Buller HR, Reitsma PH, Rosendaal FR, Cannegieter SC. Explanations for coagulation activation after air travel. J Thromb Haemost. 2010;8:971-978.
14. Allman-Farinelli MA. Obesity and venous thrombosis: A review. Semin Thromb Hemost. 2011;37:903-907.
15. Macklon NS, Greer IA, Bowman AW. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynaecol. 1997;104:191-197. (Pubitemid 27065142)
16. Pomp ER, Rosendaal FR, Doggen CJ. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol. 2008;83:97-102.
17. Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet. 2006;367:1075-1079.
18. Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med. 2011;9:1.
19. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376:1498-1509.
20. Lorenzet R, Napoleone E, Cutrone A, Donati MB. Thrombosis and obesity: cellular bases. Thromb Res. 2011.
21. van Minkelen R, de Visser MC, Houwing-Duistermaat JJ, Vos HL, Bertina RM, Rosendaal FR. Haplotypes of il1b, il1rn, il1r1, and il1r2 and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol. 2007;27: 1486-1491. (Pubitemid 46809442)
22. Morange PE, Bezemer I, Saut N, Bare L, Burgos G, Brocheton J, Durand H, Biron-Andreani C, Schved JF, Pernod G, Galan P, Drouet L, Zelenika D, Germain M, Nicaud V, Heath S, Ninio E, Delluc A, Munzel T, Zeller T, Brand-Herrmann SM, Alessi MC, Tiret L, Lathrop M, Cambien F, Blankenberg S, Emmerich J, Tregouet DA, Rosendaal FR. A follow-up study of a genome-wide association scan identifies a susceptibility locus for venous thrombosis on chromosome 6p24.1. Am J Hum Genet. 2010; 86:592-595.
23. Christiansen SC, Naess IA, Cannegieter SC, Hammerstrom J, Rosendaal FR, Reitsma PH. Inflammatory cytokines as risk factors for a first venous thrombosis: A prospective population-based study. PLoS Med. 2006; 3:e334.
24. Sevitt S. Thrombosis and embolism after injury. J Clin Pathol Suppl (R Coll Pathol). 1970;4:86-101.
25. Vanschoonbeek K, Feijge MA, Van Kampen RJ, Kenis H, Hemker HC, Giesen PL, Heemskerk JW. Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. J Thromb Haemost. 2004;2:476-484. (Pubitemid 40185661)
26. Bezemer ID, Bare LA, Doggen CJ, Arellano AR, Tong C, Rowland CM, Catanese J, Young BA, Reitsma PH, Devlin JJ, Rosendaal FR. Gene variants associated with deep vein thrombosis. JAMA. 2008;299: 1306-1314. (Pubitemid 351439076)
27. Watson HG, Chee YL. Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism. Blood Rev. 2008;22:107-116.
28. Dellas C, Schafer K, Rohm I, Lankeit M, Ellrott T, Faustin V, Riggert J, Hasenfuss G, Konstantinides S. Absence of leptin resistance in platelets from morbidly obese individuals may contribute to the increased thrombosis risk in obesity. Thromb Haemost. 2008;100:1123-1129.
29. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: Prevalence, prognostic factors, and the role of leukocytes and jak2v617f. Semin Thromb Hemost. 2007;33:313-320. (Pubitemid 46878103)
30. Lauw MN, Bus EW, van Wulfften Palthe AF, Coppens M, Homburg CH, Middeldorp S, van der Schoot CE, Koene HR, Biemond BJ. Relevance of the jak2v617f mutation in patients with deep vein thrombosis of the leg. Ann Hematol. 2012;91:103-107.
31. Spivak J. Daily aspirin-only half the answer. N Engl J Med. 2004;350: 99-101.
32. Vaya A, Mira Y, Martinez M, Villa P, Ferrando F, Estelles A, Corella D, Aznar J. Biological risk factors for deep vein trombosis. Clin Hemorheol Microcirc. 2002;26:41-53. (Pubitemid 34594133)
33. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: The longitudinal investigation of thromboembolism etiology. Arch Intern Med. 2002;162:1182-1189. (Pubitemid 34522408)
34. Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Hansen JB. Hematocrit and risk of venous thromboembolism in a general population. The tromso study. Haematologica. 2010;95:270-275.
35. Schreijer AJ, Reitsma PH, Cannegieter SC. High hematocrit as a risk factor for venous thrombosis. Cause or innocent bystander? Haematologica. 2010;95:182-184.
36. Owens AP III, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res. 2011;108:1284-1297.
37. Mackman N. The role of tissue factor and factor viia in hemostasis. Anesth Analg. 2009;108:1447-1452.
38. Berckmans RJ, Nieuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost. 2001;85:639-646. (Pubitemid 32293699)
39. Schwertz H, Tolley ND, Foulks JM, Denis MM, Risenmay BW, Buerke M, Tilley RE, Rondina MT, Harris EM, Kraiss LW, Mackman N, Zimmerman GA, Weyrich AS. Signal-dependent splicing of tissue factor pre-mrna modulates the thrombogenicity of human platelets. J Exp Med. 2006;203:2433-2440. (Pubitemid 44664613)
40. Chen YW, Chen JK, Wang JS. Strenuous exercise promotes shearinduced thrombin generation by increasing the shedding of procoagulant microparticles from platelets. Thromb Haemost. 2010;104:293-301.
41. Ye R, Ye C, Huang Y, Kiu L, Wang S. Circulating tissue factor positive microparticles in patients with acute recurrent deep venous thrombosis. Thromb Res. 2011.
42. Aleman MM, Gardiner C, Harrison P, Wolberg AS. Differential contributions of monocyte-and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. J Thromb Haemost. 2011;9:2251-2261.
43. Kushak RI, Nestoridi E, Lambert J, Selig MK, Ingelfinger JR, Grabowski EF. Detached endothelial cells and microparticles as sources of tissue factor activity. Thromb Res. 2005;116:409-419. (Pubitemid 41191193)
44. Steppich BA, Hassenpflug M, Braun SL, Schomig K, von Beckerath O, von Beckerath N, Eckstein HH, Ott I. Circulating tissue factor and microparticles are not increased in patients with deep vein thrombosis. VASA. 2011;40:117-122.
45. Garcia Rodriguez P, Eikenboom HC, Tesselaar ME, Huisman MV, Nijkeuter M, Osanto S, Bertina RM. Plasma levels of microparticleassociated tissue factor activity in patients with clinically suspected pulmonary embolism. Thromb Res. 2010;126:345-349.
46. Manly DA, Wang J, Glover SL, Kasthuri R, Liebman HA, Key NS, Mackman N. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb Res. 2010;125:511-512.
47. Bidot L, Jy W, Bidot C Jr, Jimenez JJ, Fontana V, Horstman LL, Ahn YS. Microparticle-mediated thrombin generation assay: increased activity in patients with recurrent thrombosis. J Thromb Haemost. 2008;6:913-919. (Pubitemid 351689911)
48. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost. 2007;5:520-527. (Pubitemid 46680685)
49. Tesselaar ME, Romijn FP, van der Linden IK, Bertina RM, Osanto S. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost. 2009;7:1421-1423.
50. Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, Furie B. Tumor-derived tissue factor-bearing microparticles are asso-ciated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009;15:6830-6840.
51. Sartori MT, Della Puppa A, Ballin A, Saggiorato G, Bernardi D, Padoan A, Scienza R, d'Avella D, Cella G. Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles. J Neurooncol. 2011;104:225-231.
52. Thomas GM, Panicot-Dubois L, Lacroix R, Dignat-George F, Lombardo D, Dubois C. Cancer cell-derived microparticles bearing p-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med. 2009;206:1913-1927.
53. Mukherjee SD, Swystun LL, Mackman N, Wang JG, Pond G, Levine MN, Liaw PC. Impact of chemotherapy on thrombin generation and on the protein c pathway in breast cancer patients. Pathophysiol Haemost Thromb. 2010;37:88-97.
54. Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, Maquelin KN, Roozendaal KJ, Jansen PG, ten Have K, Eijsman L, Hack CE, Sturk A. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation. 1997;96:3534-3541. (Pubitemid 27513430)
55. Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. J Thromb Haemost. 2009;7 Suppl 1:301-304.
56. Reitsma PH, Poort SR, Allaart CF, Briet E, Bertina RM. The spectrum of genetic defects in a panel of 40 dutch families with symptomatic protein c deficiency type i: heterogeneity and founder effects. Blood. 1991;78: 890-894.
57. Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:345-357.
58. Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE, Reitsma PH. Geographic distribution of the 20210 g to a prothrombin variant. Thromb Haemost. 1998;79:706-708. (Pubitemid 28163839)
59. Morelli VM, De Visser MC, Vos HL, Bertina RM, Rosendaal FR. Abo blood group genotypes and the risk of venous thrombosis: effect of factor v leiden. J Thromb Haemost. 2005;3:183-185. (Pubitemid 41647137)
60. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood. 2005;106:4176-4183. (Pubitemid 41775924)
61. Middeldorp S, Meijers JC, van den Ende AE, van Enk A, Bouma BN, Tans G, Rosing J, Prins MH, Buller HR. Effects on coagulation of levonorgestrel-and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost. 2000;84:4-8. (Pubitemid 30433659)
62. Tans G, Curvers J, Middeldorp S, Thomassen MC, Meijers JC, Prins MH, Bouma BN, Buller HR, Rosing J. A randomized cross-over study on the effects of levonorgestrel-and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 2000;84:15-21. (Pubitemid 30433661)
63. Meijers JC, Middeldorp S, Tekelenburg W, van den Ende AE, Tans G, Prins MH, Rosing J, Buller HR, Bouma BN. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor xi-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost. 2000;84:9-14. (Pubitemid 30433660)
64. Henkens CM, Bom VJ, Seinen AJ, van der Meer J. Sensitivity to activated protein c; influence of oral contraceptives and sex. Thromb Haemost. 1995;73:402-404.
65. van Vliet HA, Bertina RM, Dahm AE, Rosendaal FR, Rosing J, Sandset PM, Helmerhorst FM. Different effects of oral contraceptives containing different progestogens on protein s and tissue factor pathway inhibitor. J Thromb Haemost. 2008;6:346-351.
66. Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, Nicolaes GA, Meijers JC, Bouma BN, Buller HR, Prins MH, Tans G. Low-dose oral contraceptives and acquired resistance to activated protein c: a randomised cross-over study. Lancet. 1999;354:2036-2040.
67. van Vliet HA, Winkel TA, Noort I, Rosing J, Rosendaal FR. Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb Haemost. 2004;2: 2060-2062. (Pubitemid 40192767)
68. van Hylckama Vlieg A, Middeldorp S. Hormone therapies and venous thromboembolism: Where are we now? J Thromb Haemost. 2011;9: 257-266.
69. Eilertsen AL, Liestol S, Mowinckel MC, Hemker HC, Sandset PM. Differential impact of conventional and low-dose oral hormone therapy (ht), tibolone and raloxifene on functionality of the activated protein c system. Thromb Haemost. 2007;97:938-943. (Pubitemid 46939206)
70. Eilertsen AL, Sandvik L, Mowinckel MC, Andersen TO, Qvigstad E, Sandset PM. Differential effects of conventional and low dose oral hormone therapy (ht), tibolone, and raloxifene on coagulation and fibrinolysis. Thromb Res. 2007;120:371-379. (Pubitemid 46879904)
71. Keramaris NC, Christodoulakos GE, Lambrinoudaki IV, Dalamanga A, Alexandrou AP, Bramis J, Bastounis E, Creatsas GC. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women. Climacteric. 2007;10:400-407. (Pubitemid 47402945)
72. Hemelaar M, Kenemans P, Hack CE, Klipping C, van der Mooren MJ. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: A randomized trial. Menopause. 2008;15:248-255. (Pubitemid 351354984)
73. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: Systematic review and meta-analysis. BMJ. 2008;336: 1227-1231. (Pubitemid 351809317)
74. Brenner B. Haemostatic changes in pregnancy. Thromb Res. 2004;114: 409-414. (Pubitemid 39422573)
75. Abdollahi M, Cushman M, Rosendaal FR. Obesity: Risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost. 2003;89:493-498. (Pubitemid 36329240)
76. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev. 2002;3:85-101. (Pubitemid 34827150)
77. Rosito GA, D'Agostino RB, Massaro J, Lipinska I, Mittleman MA, Sutherland P, Wilson PW, Levy D, Muller JE, Tofler GH. Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost. 2004;91:683-689. (Pubitemid 38477447)
78. Godsland IF, Crook D, Proudler AJ, Stevenson JC. Hemostatic risk factors and insulin sensitivity, regional body fat distribution, and the metabolic syndrome. J Clin Endocrinol Metab. 2005;90:190-197. (Pubitemid 40116656)
79. Sola E, Navarro S, Medina P, Vaya A, Estelles A, Hernandez-Mijares A, Espana F. Activated protein c levels in obesity and weight loss influence. Thromb Res. 2009;123:697-700.
80. Ay L, Kopp HP, Brix JM, Ay C, Quehenberger P, Schernthaner GH, Pabinger I, Schernthaner G. Thrombin generation in morbid obesity: significant reduction after weight loss. J Thromb Haemost. 2010;8: 759-765.
81. Folsom AR, Qamhieh HT, Wing RR, Jeffery RW, Stinson VL, Kuller LH, Wu KK. Impact of weight loss on plasminogen activator inhibitor (pai-1), factor vii, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb. 1993;13:162-169. (Pubitemid 23056789)